CD8+ T cells are central to T cell–mediated antitumor responses to both neoantigens and tumor-associated antigens presented by class I human leukocyte antigen (HLA) alleles in complex with β-2 microglobulin. The gene discussed is CD8A; the disease is neoplasm.